Search results

  1. D

    Review Fatigue as the Chief Complaint: Epidemiology, Causes, Diagnosis, and Treatment 2021 Maisel et al

    So much for the concept of differential diagnosis. What happened to doctoring in the investigatory sense? What am I paying them to do, or not to do, because they get my money regardless?
  2. D

    Open The Long COVID-19 Wearable Device Study, Scripps Translational Science Institute, California

    Sorry if I'm detouring the device thing, but I NEVER EVER talk brain PEM with my doctors or familly. So this is a treat. Physical exertion can cause PEM, we all know that and most of us endure it. Brain exertion - yes, that's physical, but it's different - can cause pretty much the same set of...
  3. D

    Open The Long COVID-19 Wearable Device Study, Scripps Translational Science Institute, California

    So, good question. And as far as I can see, maybe. Brain PEM is tricky, at least for me. Clearly, sometimes HR and HRV play a role in predicting or even correlating with brain PEM. Emotions would dove tail there. Maybe forced concentrating on a study or writing like I'm doing now, but I don't...
  4. D

    Open The Long COVID-19 Wearable Device Study, Scripps Translational Science Institute, California

    I cannot see how these devices can help with brain PEM. They do seem to offer ways to avoid overdoing it physically. And as @Kitty pointed out, for newbies what a potential godsend. But the longer Ive been sick, the more the onset of brain PEM destroys who I am and what I can tackle...
  5. D

    Review Post Viral Pain, Fatigue, and Sleep Disturbance Syndromes: Current knowledge and Future Directions, 2023, Tackey

    First sentence of the abstract slips into assumption with the unequivocal "has recovered".
  6. D

    New developments in understanding chronic illness, Nov. 8-10 Washington DC Davis/Hanson

    Curious they used "persistent" as a qualifier in this context, perhaps even more so with Dr. Kim Lewis there. I'd gladly pay way too much to be seated at the same table as Nath, Hanson and Lewis. Persistence - or at least persisters -would likely have come up at some point. It's been my...
  7. D

    New developments in understanding chronic illness, Nov. 8-10 Washington DC Davis/Hanson

    You may be right. I was mildly taken aback at the thought the NIH at any meaningful level would suggest persistence. Could you help my brain reconcile your take with this other tweet that seems to suggest something different? I appreciate the handicap that trying to interpret tweets (vs the...
  8. D

    New developments in understanding chronic illness, Nov. 8-10 Washington DC Davis/Hanson

    If this proves to be their finding, it may be important to remember this is the US. There likely will be major institutional resistance. Strike that. There will be depending on which pathogens they invite to the party. I don't want to get ahead of the results, though. But, yeah, politics and...
  9. D

    New developments in understanding chronic illness, Nov. 8-10 Washington DC Davis/Hanson

    What an odd statement. If you embrace a persistent pathogen theory, how do you decide which pathogens can be at play, which cannot? That to me would seem one part huge undertaking, and one part dangerous politics.
  10. D

    New Oxford Textbook of Psychiatry, 2012 and 2020 editions - Sharpe et al on CFS

    If their target audience was medical students, what better way to start teaching those future clinicians and researchers that it's "such patients" who present as an unstable challenge to "medical authority", than in a textbook, presumably used in medschool. The authors literally pit future...
  11. D

    New Oxford Textbook of Psychiatry, 2012 and 2020 editions - Sharpe et al on CFS

    Textbooks are more dangerous than studies or articles. Textbooks carry an implied imprimatur of codified authority. Perhaps more damaging, textbooks imprint. Then they endure as authenticated reference materials, from classrooms and lecture halls to home studies and bookshelves. Hard to...
  12. D

    New Lyme Treatment

    https://www.bayarealyme.org/blog/research-funded-by-bay-area-lyme-foundation-identifies-new-investigational-therapy-regimen-capable-of-irreversibly-damaging-lyme-bacteria-in-laboratory-tests/ In vitro tested, so early yet.
  13. D

    The LIFT trial (OMF) - Pyridostigmine (mestinon) and Low Dose Naltrexone (LDN)

    Which of course got its start in the US at the University of Rochester. :)
Back
Top Bottom